Patents by Inventor Jing AI

Jing AI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210134154
    Abstract: A parallel remote control driving system for an intelligent network vehicle, comprising an intelligent network vehicle control device, a parallel driving control and a remote control driving device. The remote control driving device can generate, according to a remote control driving request signal from the parallel driving control device, a remote control driving instruction signal, and generates, according to user operations, a driving mode signal and a vehicle control signal and transmits the vehicle control signal to the intelligent network vehicle control device through the parallel driving control device, so as to realize a remote control of the intelligent network vehicle. With the parallel remote control driving system, the human driver is no longer necessary when the intelligent network vehicle is on the road.
    Type: Application
    Filed: April 19, 2018
    Publication date: May 6, 2021
    Applicant: QINGDAO VEHICLE INTELLIGENCE PIONEERS INCORPORATION
    Inventors: Feiyue WANG, Bin TIAN, Yunfeng AI, Long CHEN, Jing LI, Li LI, Dongpu CAO
  • Patent number: 10988456
    Abstract: An o-aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data shows that the o-aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: April 27, 2021
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Youhong Hu, Meiyu Geng, Wenming Ren, Jian Ding, Xiaocong Guan, Jing Ai, Lang Wang, Xia Peng, Yang Liu, Yang Dai, Limin Zeng
  • Publication number: 20210078972
    Abstract: The present invention relates to quinoline or quinazoline compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a prodrug molecule thereof, or a deuterated compound thereof. The compound of the present invention is effective in inhibiting the action of AXL protein kinase and can inhibit proliferation, migration, and invasion of various tumor cells. Further, the quinoline or quinazoline compound of the present invention has excellent metabolic stability, high in vivo antitumor activity, low toxic side effects, and can be used for preparing a drug for preventing hyperproliferative diseases such as tumors in humans and other mammals.
    Type: Application
    Filed: March 29, 2019
    Publication date: March 18, 2021
    Inventors: Ke DING, Meiyu GENG, Shingpan CHAN, Jian DING, Li TAN, Jing AI, Zhang ZHANG, Xia PENG, Xiaomei REN, Yinchun JI, Zhengchao TU, Yang DAI, Xiaoyun LU
  • Publication number: 20200319057
    Abstract: The present invention relates to a method for acquiring the water leakage amount of a leakage area in a water distribution system. In the method, a hydraulic model is coupled with monitored data, and the water leakage amounts of different areas in the water distribution system are obtained through inversion by optimizing the spatial distribution of water leakage amounts. In addition to the coupling of the hydraulic model with the monitored data, virtual sectorization and pipe leakage risk assessment are used. By using a minimum difference between a simulated value and a monitored value at a pressure measurement point as a target, the water leakage amounts of different areas in the water distribution system are calculated by an optimization algorithm. Compared with the prior art, the present invention actualizes the effective identification of leakage areas in a water distribution system with a high leakage rate (i.e., with many leakage points).
    Type: Application
    Filed: October 13, 2019
    Publication date: October 8, 2020
    Inventors: Tao TAO, Jing AI, Kui ZHANG, Hexiang YAN, Kunlun XIN, Shuping LI
  • Patent number: 10710996
    Abstract: The present invention discloses a pyrido-azacyclic compound represented by formula I, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a preparation process thereof and a composition comprising the compound, and a use thereof as a multi-target protein kinase inhibitor in the preparation of a medicament for the treatment of diseases that are associated with protein kinase, especially c-Met, such as cancer and the like. The compound represented by formula I has potent inhibitory activity on tumor cells with overexpression of c-Met kinase, can effectively target c-Met-mediated signaling pathway, and can be used in the treatment of diseases such as cancer and the like that is caused by the overexpression of c-Met kinase.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: July 14, 2020
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Yaqiu Long, Meiyu Geng, Zhongliang Xu, Jing Ai
  • Patent number: 10683278
    Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 16, 2020
    Assignees: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD., JINAN UNIVERSITY, SHANGHAI INTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Ke Ding, Meiyu Geng, Li Tan, Jian Ding, Zhang Zhang, Jing Ai, Xiaomei Ren, Donglin Gao, Zhengchao Tu, Xiaoyun Lu, Dongmei Zhang
  • Publication number: 20200172510
    Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 4, 2020
    Inventors: Ao ZHANG, Meiyu GENG, Li XING, Jing AI, Zilan SONG, Xia PENG, Wangting GU, Jian DING
  • Publication number: 20200055838
    Abstract: An o-aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data shows that the o-aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses.
    Type: Application
    Filed: February 12, 2018
    Publication date: February 20, 2020
    Inventors: Youhong HU, Meiyu GENG, Wenming REN, Jian DING, Xiaocong GUAN, Jing AI, Lang WANG, Xia PENG, Yang LIU, Yang DAI, Limin ZENG
  • Patent number: 10562900
    Abstract: The present invention provides an indazole compound as a FGFR kinase inhibitor, preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), wherein the definitions of each group are described in the specification. The compound of the present invention has good FGFR kinase-inhibiting activity, and can be used in preparing a series of medicines for treating FGFR kinase activity related diseases.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: February 18, 2020
    Assignees: Shanghai Haihe Pharmaceutical Co., Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Meiyu Geng, Lei Liu, Lei Jiang, Min Huang, Chuantao Zha, Jing Ai, Lei Wang, Jianhua Cao, Jian Ding
  • Publication number: 20190367520
    Abstract: A new compound having an FGFR inhibitory activity and preparation and application thereof are provided. In particular, the compound according to the invention has a structure as shown in formula I, in which each group and substituent are as defined in the description. Also, a preparation method for the compound and a use thereof in preparation of a drug for treating and/or preventing a tumor-related disease and/or an FGFR-related disease are provided.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 5, 2019
    Inventors: Wenhu DUAN, Meiyu GENG, Yuming WANG, Jing AI, Jun FAN, Yang DAI, Jian DING
  • Publication number: 20190135818
    Abstract: The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.
    Type: Application
    Filed: May 24, 2017
    Publication date: May 9, 2019
    Inventors: Hualiang JIANG, Hong LIU, Meiyu GENG, Mingyue ZHENG, Jing AI, Yulan WANG, Xiaowei WU, Shuangjie LI, Xia PENG, Chunpu LI, Kaixian CHEN, Bao WANG
  • Publication number: 20180265496
    Abstract: Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.
    Type: Application
    Filed: August 18, 2016
    Publication date: September 20, 2018
    Applicants: JINAN UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA,CHINESE ACADEMY OF SCIENCES
    Inventors: Ke DING, Meiyu GENG, Li TAN, Jian DING, Zhang ZHANG, Jing AI, Xiaomei REN, Donglin GAO, Zhengchao TU, Xiaoyun LU, Dongmei ZHANG
  • Publication number: 20180244667
    Abstract: The present invention discloses a pyrido-azacyclic compound represented by formula I, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a preparation process thereof and a composition comprising the compound, and a use thereof as a multi-target protein kinase inhibitor in the preparation of a medicament for the treatment of diseases that are associated with protein kinase, especially c-Met, such as cancer and the like. The compound represented by formula I has potent inhibitory activity on tumor cells with overexpression of c-Met kinase, can effectively target c-Met-mediated signaling pathway, and can be used in the treatment of diseases such as cancer and the like that is caused by the overexpression of c-Met kinase.
    Type: Application
    Filed: May 23, 2016
    Publication date: August 30, 2018
    Inventors: Yaqiu LONG, Meiyu GENG, Zhongliang XU, Jing AI
  • Patent number: 10058566
    Abstract: A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerizing factor activity inhibitors and actin-aggregation inhibitors.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: August 28, 2018
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
    Inventors: Jian Ding, Jing Ai, Yi Chen, Xun Huang
  • Publication number: 20170275291
    Abstract: The present invention provides an indazole compound as a FGFR kinase inhibitor, preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), wherein the definitions of each group are described in the specification. The compound of the present invention has good FGFR kinase-inhibiting activity, and can be used in preparing a series of medicines for treating FGFR kinase activity related diseases.
    Type: Application
    Filed: August 19, 2015
    Publication date: September 28, 2017
    Applicants: Shanghai Haihe Pharmaceutical Co., Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Meiyu GENG, Lei LIU, Lei JIANG, Min HUANG, Chuantao ZHA, Jing AI, Lei WANG, Jianhua CAO, Jian DING
  • Patent number: 9567342
    Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: February 14, 2017
    Assignees: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
    Inventors: Weibo Wang, Meiyu Geng, Jian Ding, Xingdong Zhao, Jing Ai, Qiang Tian, Xia Peng, Weipeng Zhang, Hongbin Liu, Haohan Tan, Ling Chen
  • Publication number: 20160367591
    Abstract: A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerising factor activity inhibitors and actin-aggregation inhibitors.
    Type: Application
    Filed: July 2, 2014
    Publication date: December 22, 2016
    Inventors: Jian Ding, Jing Ai, Yi Chen, Xun Huang
  • Publication number: 20160145244
    Abstract: Provided are certain ALK inhibitors, pharmaceutical compositions thereof, and methods of use therefor.
    Type: Application
    Filed: November 19, 2015
    Publication date: May 26, 2016
    Applicant: FOCHON PHARMA, INC.
    Inventors: Weibo Wang, Meiyu Geng, Jian Ding, Xingdong Zhao, Jing Ai, Huajie Zhang, Xia Peng
  • Publication number: 20160046638
    Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Inventors: Weibo WANG, Meiyu GENG, Jian DING, Xingdong ZHAO, Jing AI, Qiang TIAN, Xia PENG, Weipeng ZHANG, Hongbin LIU, Haohan TAN, Ling CHEN
  • Patent number: 9206166
    Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: December 8, 2015
    Assignees: Shanghai Institute of Materia Medica Academy of Sciences, Shanghai Fochon Pharmaceutical Co., LTD
    Inventors: Weibo Wang, Meiyu Geng, Jian Ding, Xingdong Zhao, Jing Ai, Qiang Tian, Xia Peng, Weipeng Zhang, Hongbin Liu, Haohan Tan, Ling Chen